DEVELOPMENT AND VALIDATION OF AN IMAGING-BASED BIOMARKER OF THERAPEUTIC EFFICACY
基于成像的治疗效果生物标志物的开发和验证
基本信息
- 批准号:7990122
- 负责人:
- 金额:$ 18.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-14 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAftercareAlgorithmsAngiogenesis InhibitorsAnimal ModelAnimalsApoptosisApplications GrantsAreaBiologic CharacteristicBiologicalBiological AssayBiological MarkersBiological ModelsBlood VesselsCancer PatientCell ProliferationCellularityClassificationClinicalClinical TrialsDataDetectionDevelopmentDiagnosticDiffusionDiffusion Magnetic Resonance ImagingDimethylxanthenone Acetic AcidDisorder by SiteDoseDrug Delivery SystemsEvaluationExhibitsFeedbackFunctional ImagingFutureGoalsGrowthHead and Neck Squamous Cell CarcinomaHead and neck structureHeterogeneityHistologicImageImmunohistochemistryIn SituIndividualInterleukin-6Ionizing radiationMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of lungMeasuresMediator of activation proteinMethodsModelingMolecularMolecular BiologyMonitorMultivariate AnalysisMusNecrosisNeoplasms in Vascular TissueNormal tissue morphologyOperative Surgical ProceduresOutcomePatient SelectionPatientsPermeabilityPharmacodynamicsPhase I Clinical TrialsPhase II Clinical TrialsPhysiologyPlayPoisonPositron-Emission TomographyPre-Clinical ModelPreclinical Drug EvaluationPredispositionProtocols documentationPublishingRadioactive TracersResearch ProposalsResolutionRoleSafetyScheduleSerotoninSiteSolid NeoplasmSpecimenSquamous cell carcinomaStatistical ModelsSystemTechniquesTestingTherapeuticTherapeutic AgentsTissuesTranslationsTransplantationTreatment EfficacyTreatment outcomeTumor Cell LineTumor Necrosis Factor-alphaTumor TissueTumor VolumeTumor-DerivedValidationVascular PermeabilitiesWeightX-Ray Computed TomographyXenograft procedureangiogenesisanticancer treatmentbasecancer therapycell killingchemotherapeutic agentchemotherapyclinical applicationclinically relevantcohortcytotoxicdensityhuman TNF proteinimaging modalityin vivointerestirinotecanmolecular markerneoplastic cellnoveloncologypatient populationpre-clinicalpreclinical evaluationpreclinical studyprognosticprospectivepublic health relevanceresearch clinical testingresearch studyresponsesoft tissuestandard measuresuccesstumortumor growthtumor xenograftvalidation studies
项目摘要
DESCRIPTION (provided by applicant): Successful clinical evaluation of targeted therapies is dependent on the development of noninvasive imaging methods to characterize early vascular and cellular changes in situ following treatment. In this application, we propose to non-invasively monitor the effects of vascular-targeted therapy in vivo using magnetic resonance imaging (MRI) with the overall goal of identifying and validating early imaging biomarkers that are predictive of treatment outcome. Studies will be carried out using primary patient tumor-derived xenografts of squamous cell carcinomas of the head and neck (SCCHN) following treatment with a tumor vascular disrupting agent (tumor-VDA), 5,6-dimethylxanthenone-4-acetic acid (DMXAA) alone and in combination with the chemotherapeutic agent, Irinotecan. Three MRI methods, (i) T1-weighted dynamic contrast-enhanced MRI (DCE-MRI), (ii) T2*weighted intrinsic susceptibility MRI, and (iii) diffusion-weighted MRI (DW-MRI) will be employed to measure the vascular and cellular response of SCCHN patient tumor xenografts to VDA chemotherapy. It is our hypothesis that quantitative changes in these MRI parameters obtained shortly after treatment will serve as indicators of therapeutic efficacy. To test this hypothesis, we will carry out systematic and rigorous statistical analyses powered to detect correlation between imaging and non-imaging variables with treatment outcome using clinically applicable end points. Suitable algorithms and statistical models will be used to evaluate the association between imaging parameters and underlying molecular mechanisms and to allow detection of response variables that are predictive of therapeutic efficacy. Once developed, we will prospectively validate the prediction algorithm in a separate cohort using the same treatment conditions. Based on our encouraging preliminary results, we envision successful identification and validation of an imaging biomarker that could be applied in future clinical trials in cancer patients irrespective of the disease site. Understanding these tissue-specific changes following treatment would assist in the optimization and clinical application of vascular-targeted therapies. The specific aims are: Aim 1. To monitor vascular and cellular response to VDA chemotherapy using MRI Aim 2. To evaluate the association between imaging data and underlying molecular mechanisms Aim 3. To identify and validate the ability of imaging markers to predict outcome
PUBLIC HEALTH RELEVANCE: The overall focus of this proposal is to non-invasively monitor the effects of vascular-targeted therapy in vivo using magnetic resonance imaging (MRI) with the goal of identifying and validating early imaging biomarkers of treatment outcome. Using primary patient tumor xenografts, we plan to carry out a systematic and rigorous statistical evaluation into the predictive ability of MRI biomarkers along with association of individual imaging parameters to underlying mechanisms. We envision successful identification and validation of an MRI response biomarker that could potentially be applied in future clinical trials.
描述(申请人提供):靶向治疗的成功临床评估依赖于非侵入性成像方法的发展,以表征治疗后早期血管和细胞的原位变化。在这一应用中,我们建议使用磁共振成像(MRI)在体内非侵入性地监测血管靶向治疗的效果,总体目标是识别和验证预测治疗结果的早期成像生物标记物。研究将使用原发患者头颈部鳞状细胞癌(SCCHN)肿瘤来源的异种移植,在接受肿瘤血管干扰剂(Tumor-VDA)、5,6-二甲基黄原酮-4-乙酸(DMXAA)单独治疗并与化疗药物伊立替康联合治疗后进行。我们将使用三种MRI方法,(I)T1加权动态对比增强MRI(DCE-MRI),(Ii)T2*加权固有敏感性MRI,(Iii)扩散加权MRI(DW-MRI)来测量SCCHN患者肿瘤移植瘤对VDA化疗的血管和细胞反应。我们的假设是,在治疗后不久获得的这些MRI参数的量化变化将作为治疗效果的指标。为了验证这一假设,我们将使用临床适用的终点进行系统和严格的统计分析,以检测成像和非成像变量与治疗结果之间的相关性。适当的算法和统计模型将被用来评估成像参数和潜在的分子机制之间的关联,并允许检测预测治疗效果的反应变量。一旦开发完成,我们将使用相同的治疗条件在单独的队列中前瞻性地验证预测算法。基于我们令人鼓舞的初步结果,我们设想成功识别和验证一种成像生物标记物,该标记物可以应用于未来癌症患者的临床试验,而不考虑疾病的部位。了解治疗后这些组织特异性的变化将有助于血管靶向治疗的优化和临床应用。具体目标是:目标1.使用MRI Aim监测血管和细胞对VDA化疗的反应2.评估影像数据与潜在分子机制之间的联系目标3.识别和验证影像标记物预测结果的能力
公共卫生相关性:这项提案的总体重点是使用磁共振成像(MRI)在体内非侵入性地监测血管靶向治疗的效果,目的是识别和验证治疗结果的早期成像生物标志物。利用原发患者的肿瘤异种移植,我们计划对MRI生物标记物的预测能力以及个体成像参数与潜在机制的关联进行系统和严格的统计评估。我们设想成功地识别和验证一种MRI反应生物标记物,该标记物可能在未来的临床试验中应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mukund Seshadri其他文献
Mukund Seshadri的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mukund Seshadri', 18)}}的其他基金
Radiation-induced Salivary Gland Vascular Injury: Mechanisms and Interventions
辐射引起的唾液腺血管损伤:机制和干预措施
- 批准号:
10701306 - 财政年份:2022
- 资助金额:
$ 18.47万 - 项目类别:
Acquisition of a 7T MR scanner for Translational Imaging Research at Roswell Park
购买一台 7T MR 扫描仪用于罗斯威尔公园的转化成像研究
- 批准号:
10176803 - 财政年份:2021
- 资助金额:
$ 18.47万 - 项目类别:
Radiogenomic Credentialing of Head and Neck Cancer Models
头颈癌模型的放射基因组学认证
- 批准号:
10529301 - 财政年份:2020
- 资助金额:
$ 18.47万 - 项目类别:
Radiogenomic Credentialing of Head and Neck Cancer Models
头颈癌模型的放射基因组学认证
- 批准号:
10310511 - 财政年份:2020
- 资助金额:
$ 18.47万 - 项目类别:
Non-invasive assessment of salivary gland function: Translational Studies
唾液腺功能的无创评估:转化研究
- 批准号:
9082643 - 财政年份:2016
- 资助金额:
$ 18.47万 - 项目类别:
Impact of Vitamin D on the Chemopreventive Efficacy of Erlotinib against Oral Cancer
维生素 D 对厄洛替尼口腔癌化学预防效果的影响
- 批准号:
9257368 - 财政年份:2016
- 资助金额:
$ 18.47万 - 项目类别:
Impact of Vitamin D on the Chemopreventive Efficacy of Erlotinib against Oral Cancer
维生素 D 对厄洛替尼口腔癌化学预防效果的影响
- 批准号:
10215646 - 财政年份:2016
- 资助金额:
$ 18.47万 - 项目类别:
Photoacoustic Micro-Imaging system for Shared Tumor Imaging Resource at Roswell P
Roswell P 共享肿瘤成像资源的光声微成像系统
- 批准号:
8247498 - 财政年份:2012
- 资助金额:
$ 18.47万 - 项目类别:
DEVELOPMENT AND VALIDATION OF AN IMAGING-BASED BIOMARKER OF THERAPEUTIC EFFICACY
基于成像的治疗效果生物标志物的开发和验证
- 批准号:
8089501 - 财政年份:2010
- 资助金额:
$ 18.47万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 18.47万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 18.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 18.47万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 18.47万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 18.47万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 18.47万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 18.47万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 18.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 18.47万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 18.47万 - 项目类别: